55142-85-3 Usage
Description
Ticlopidine is a thienopyridine derivative, specifically 5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridine hydrochloride (Ticlid), known for its antiplatelet properties. It is effective in reducing cardiac events in patients with unstable angina and cerebrovascular events in the secondary prevention of stroke. Ticlopidine belongs to the thienopyridine class and has a similar mechanism of action to clopidogrel, inhibiting the purinergic receptors on platelets.
Uses
Used in Cardiovascular Applications:
Ticlopidine is used as an antiplatelet drug for the treatment of ischemic heart diseases. It suppresses the aggregation of thrombocytes and possesses antiaggregant activity, which is believed to be connected to its effect on thrombocyte membranes and the reduction in the quantity of released adenosine diphosphate and serotonin, which facilitate thrombocyte aggregation. In clinical trials, ticlopidine has demonstrated advantages over aspirin in treating cardiovascular conditions.
Used in Cerebrovascular Applications:
Ticlopidine is used in the secondary prevention of stroke, helping to reduce the risk of cerebrovascular events in patients with a history of stroke or transient ischemic attack (TIA). Its antiplatelet properties contribute to its effectiveness in this application.
Therapeutic Function
Platelet aggregation inhibitor
World Health Organization (WHO)
Ticlopidine, an inhibitor of platelet aggregation, was introduced in
1978 for use as an antithrombotic agent. By 1982 its use had been associated with
cases of agranulocytosis, severe leucopenia and impaired haemostasis. The drug
remains available in most countries in which it was approved with appropriate
warnings in the product information.
Synthesis
Ticlopidine, 5-(o-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine
(24.2.1), is synthesized in many different ways. The first way consists of N-alkylation
of 4,5,6,7-tetrahydrothieno[3,2-c]pyridine with 2-chlorobenzylchloride.
Check Digit Verification of cas no
The CAS Registry Mumber 55142-85-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,5,1,4 and 2 respectively; the second part has 2 digits, 8 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 55142-85:
(7*5)+(6*5)+(5*1)+(4*4)+(3*2)+(2*8)+(1*5)=113
113 % 10 = 3
So 55142-85-3 is a valid CAS Registry Number.
InChI:InChI=1/C14H14ClNS/c15-13-4-2-1-3-11(13)9-16-7-5-14-12(10-16)6-8-17-14/h1-4,6,8H,5,7,9-10H2
55142-85-3Relevant articles and documents
Inhibition of platelet activation, aggregation and/or adhesion by hypothermia
-
, (2016/06/28)
A method for treating acute coronary syndromes (i.e., unstable angina or non-Q-wave MI) or transient ischemic attacks in a human or animal patient by placing a heat exchange apparatus in the patient's vasculature and using that heat exchange apparatus to cool the patient to a temperature (e.g. 30-36 degrees C.) at which platelet inhibition (i.e., inhibition of platelet activation and/or aggregation and/or adhesion) occurs. Anti-shivering drugs or anesthesia may be administered to patients whose body temperature is cooled below that patient's shivering threshold (typically approximately 35.5 degrees C.). If it is determined that platelet inhibition is no longer desirable, such as when the patient is about to undergo a surgical or interventional procedure wherein bleeding could be problematic, the hypothermia-induced platelet inhibition may be rapidly reversed by using the intravascular heat exchange apparatus to re-warm the patient's body to normothermia or near normothermia.
METHOD OF PREPARING THIENO[3,2-C]PYRIDINE DERIVATIVES AND INTERMEDIATES USED THEREIN
-
Page/Page column 22-23, (2010/02/14)
Ticlopidine and clopidogrel having high blood platelet aggregation inhibitory and anti-thrombotic activities are simply prepared by reacting a substituted thiophene derivative with a 2-chlorobenzylamine derivative.
MEDICINAL COMPOSITIONS
-
, (2008/06/13)
The present invention relates to a granular pharmaceutical composition comprising a drug having a disagreeable taste, a wax and a sugar alcohol; a method for preparing the same; and a pharmaceutical product for oral administration, comprising the granular composition. The product excellently masks a disagreeable taste possessed by a drug and provides good sensation upon oral administration, and therefore is easily ingested by even the elderly, children, and patients suffering dysphagia. Moreover, the product is suitable for administration using tube.